文献速递心力衰竭与心肌病

新发心力衰竭患者心室功能改善与治疗持续时间:心力衰竭优化研究

Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study.
PubMed 文献 · Eur Heart J · 2024-01-01

本研究纳入598例LVEF≤35%的新发HFrEF患者,在起始指南推荐药物治疗后,观察LVEF改善情况。结果显示,90天时46%患者LVEF改善>35%,至180天时该比例增至68%;持续优化治疗至少180天与额外LVEF改善相关,有助于预防性ICD治疗决策。

要点

  • 新发HFrEF患者起始指南推荐药物治疗后,90天时46%达到LVEF改善>35%。
  • 持续优化治疗至180天,LVEF改善>35%的总比例增至68%。
  • 治疗优化至少180天有助于预防性ICD治疗决策。

核心结论

  • 对新发HFrEF患者持续优化指南推荐药物治疗至少180天,与额外LVEF改善>35%相关,有助于更好决策预防性ICD治疗。

研究设计与样本

  • 研究纳入2017至2022年间来自68个中心、LVEF≤35%且处方可穿戴心律转复除颤器的新发HFrEF患者,先进行3个月注册阶段,随后进入长达1年的研究阶段。

主要发现

  • 共598例新发HFrEF患者进入研究阶段,年龄59岁(四分位距51-68),女性占27%。
  • 前180天内,β受体阻滞剂、肾素-血管紧张素系统抑制剂和盐皮质激素受体拮抗剂的剂量显著增加(P < .001)。
  • 第90天时,46%[95%CI 41%-50%]的研究阶段患者LVEF改善>35%。
  • 第90天LVEF持续低的患者中,46%(95%CI 40%-52%)至第180天时LVEF改善>35%,使总改善率>35%增至68%(95%CI 63%-72%)。
  • 在随访360天的392例患者中,77%(95%CI 72%-81%)观察到LVEF改善>35%;至第90天,24例(1.8%)可穿戴心律转复除颤器佩戴者发生持续性室性心动过速,90天后无持续性室性心动过速发生。

临床怎么用

  • 对新发HFrEF患者,应持续优化指南推荐药物治疗至少180天,以评估LVEF改善情况并指导预防性ICD植入决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: In patients with de novo heart failure with reduced ejection fraction (HFrEF), improvement of left ventricular ejection fraction (LVEF) is expected to occur when started on guideline-recommended medical therapy. However, improvement may not be completed within 90 days. METHODS: Patients with HFrEF and LVEF ≤ 35% prescribed a wearable cardioverter-defibrillator between 2017 and 2022 from 68 sites were enrolled, starting with a registry phase for 3 months and followed by a study phase up to 1 year. The primary endpoints were LVEF improvement > 35% between Days 90 and 180 following guideline-recommended medical therapy initiation and the percentage of target dose reached at Days 90 and 180. RESULTS: A total of 598 patients with de novo HFrEF [59 years (interquartile range 51-68), 27% female] entered the study phase. During the first 180 days, a significant increase in dosage of beta-blockers, renin-angiotensin system inhibitors, and mineralocorticoid receptor antagonists was observed (P < .001). At Day 90, 46% [95% confidence interval (CI) 41%-50%] of study phase patients had LVEF improvement > 35%; 46% (95% CI 40%-52%) of those with persistently low LVEF at Day 90 had LVEF improvement > 35% by Day 180, increasing the total rate of improvement > 35% to 68% (95% CI 63%-72%). In 392 patients followed for 360 days, improvement > 35% was observed in 77% (95% CI 72%-81%) of the patients. Until Day 90, sustained ventricular tachyarrhythmias were observed in 24 wearable cardioverter-defibrillator carriers (1.8%). After 90 days, no sustained ventricular tachyarrhythmia occurred in wearable cardioverter-defibrillator carriers. CONCLUSIONS: Continuous optimization of guideline-recommended medical therapy for at least 180 days in HFrEF is associated with additional LVEF improvement > 35%, allowing for better decision-making regarding preventive implantable cardioverter-defibrillator therapy.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Veltmann, Duncker, Doering, et al. Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study. Eur Heart J. 2024. PMID: 38864173. doi:10.1093/eurheartj/ehae334

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。